- Home
- AEON
AEON
AEON Biopharma Inc.
as 11-15-2024 4:00pm EST
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 36.4M | IPO Year: | N/A |
| Target Price: | $5.00 | AVG Volume (30 days): | 106.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.60 - $17.17 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest AEON Biopharma Inc. News
AEON Breaking Stock News: Dive into AEON Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
2 months ago
AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting
Zacks
3 months ago
AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
GlobeNewswire
3 months ago
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
GlobeNewswire
3 months ago
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
MT Newswires
4 months ago
Top Premarket Gainers
MT Newswires
4 months ago
AEON Biopharma Plans to Pursue Biosimilar Regulatory Pathway for ABP-450
GlobeNewswire
4 months ago
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
Compare AEON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AEON AEON Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.